Nuvation Bio Inc. Shareholders' Equity
Nuvation Bio Inc. (NUVB) had Shareholders' Equity of $253.86 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $253.86M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $319.56M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $305.72M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $325.88M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $253.86M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $319.56M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $305.72M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $325.88M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $372.91M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $419.46M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $463.79M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $502.71M 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $257.19M 10-Q · filed 2025-11-03 | |
| 2024-03-31 | $594.04M 10-Q · filed 2025-11-03 | |
| 2023-12-31 | $605.12M 10-K · filed 2026-03-02 | |
| 2023-09-30 | $611.59M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $624.63M 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $641.07M 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $655.08M 10-K · filed 2025-03-06 | |
| 2022-09-30 | $667.93M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $693.08M 10-Q · filed 2023-11-02 | |
| 2022-03-31 | $723.56M 10-Q · filed 2023-11-02 | |
| 2021-12-31 | $746.00M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $769.37M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $788.93M 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $806.34M 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $215.08M 10-K · filed 2023-03-15 | $5.00M 10-K · filed 2021-03-11 |
| 2020-09-30 | $91.85M 10-Q · filed 2021-11-10 | $5.00M 10-Q · filed 2020-11-16 |
| 2020-06-30 | $102.88M 10-Q · filed 2021-11-10 | $24.00K 10-Q · filed 2020-08-14 |
| 2020-04-23 | $0.00 10-K/A · filed 2021-05-21 | |
| 2020-03-31 | $110.16M 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $117.75M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |